Understanding Celiac Disease From Genetics to the Future Diagnostic Strategies

Carolina Salazar, Jennyfer M García-Cárdenas and César Paz-y-Miño

Centro de Investigación Genética y Genómica, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador.

ABSTRACT: Celiac disease (CD) is an autoimmune disorder characterized by the permanent inflammation of the small bowel, triggered by the ingestion of gluten. It is associated with a number of symptoms, the most common being gastrointestinal. The prevalence of this illness worldwide is 1%. One of the main problems of CD is its difficulty to be diagnosed due to the various presentations of the disease. Besides, in many cases, CD is asymptomatic. Celiac disease is a multifactorial disease, HLA-DQ2 and HLA-DQ8 haplotypes are predisposition factors. Nowadays, molecular markers are being studied as diagnostic tools. In this review, we explore CD from its basic concept, manifestations, types, current and future methods of diagnosis, and associated disorders. Before addressing the therapeutic approaches, we also provide a brief overview of CD genetics and treatment.

KEYWORDS: Celiac disease, HLA, gluten, polymorphisms

Introduction

Celiac disease (CD) is an autoimmune disease that is characterized by the permanent inflammation of the small bowel and is triggered by the ingestion of food containing gluten such as wheat, oat, barley, and rye. Small bowel inflammation occurs due to a genetic predisposition of individuals who are carriers of haplotypes HLA-DQ2 and HLA-DQ8.[1] This inflammation affects the proximal region of the small bowel and is conserved in the distal ileum. However, the small bowel has functional reserves, which explains why some individuals do not have mild or malabsorption symptoms.[2]

Celiac disease was first described in 1887 by Samuel Gee who described the classic symptoms: diarrhea, poor growth, and fatigue. Gee stated that treatment is based on a gluten-free diet. Later, Paulley et al were the first to analyze biopsy samples of patients with CD and found an extensive flattening of the villi and chronic inflammation of the small bowel cells.[1,3]

Gluten is a set of proteins that serve as storage contained in the endosperm of certain cereal grains such as wheat, oats, barley, and rye. The endosperm is the raw material used to produce flour for bakery products and gives breads their chewy texture.[4] These proteins can be divided into 2 fractions by their solubility in alcohol: soluble gliadins and insoluble glutenins; each has 2 or 3 different structural domains.[5]

The α/β-gliadin and γ-gliadin are the most abundant in foods containing gluten but differ mainly in their C-terminal and N-terminal domains. The α/β-gliadin presents the QPQPFPQQPYP peptide in the N-terminal end, whereas γ-gliadin contains QPQQPFP peptide. The C-terminal does not have repeating units and has fewer glutamine and proline residues compared with the N-terminal. Moreover, glutenins are divided according to their molecular weight in high-molecular-weight (HMW) and low-molecular-weight (LMW) glutenins. The LMW glutenins are mostly present in gluten.[5] Table 1 presents the most common foods that contain gluten and their derivatives as well as a list of gluten-free products.

Gluten triggers the immune response in CD when there is a deficiency of prolyl endopeptidase (PEP) enzymes in the digestive tract. These proteins are not degraded and, as a result, are accumulated in the lumen of the small intestine where they cannot pass the intestinal epithelium. Endogenous and exogenous agents present in the gut lumen affect cell permeability allowing the passage of proteins into the lamina propria where they will be used as a substrate for transglutaminase 2. This enzyme converts glutamine residues to glutamate. The resulting peptides have affinity for the HLA-DQ2/DQ8 molecules (exposed on the antigen-presenting cells).[6]

The antigen-presenting cells are found in the lamina propria and present a complex enzyme peptide. As a result, CD4+ T cells are activated triggering a T_H1 response. This produces antigliadin antibody (AGA) and anti-transglutaminase antibody. Gamma interferon is released, and presentation of the antigen to the HLA molecules increases. This increases the expression of ligands that are recognized by T cells.[7]

Celiac disease also increases the number of CD3+ intraepithelial lymphocytes followed by identification of T_H17 T cells involved in the pathogenesis of autoimmune diseases. Interleukin (IL)-23, T_H17-associated cytokine, and IL-17A IL1β are also implicated in CD.[8]

Table 1. Food containing gluten, their derivatives, and gluten-free foods.

SOURCE OF GLUTEN	DERIVATIVES	GLUTEN-FREE FOOD
Oats (unless labeled gluten-free)[7]	Oat flour, oat bran, oat gums, oat fiber, and oat groats[8]	Fruits and vegetables (except oat, wheat, barley, rye, semolina, and farina)
Wheat[9]	Sauces, gravies, wheat flour, wheat starch, soups, processed meats and fish, wieners,[9] graham flour, wheat germ, pancakes, triticale,[7] durum, einkorn, emmer, farro, kamut, spelt, pasta,[10] cake, bread, cupcakes, bagels, pizza crust, pastries, donuts, pie crust, hot dog and sandwich buns,[11] panko, and udon[8]	All unprocessed meat: chicken, beef, pork, fish, and eggs Condiments: ketchup, mayonnaise, salt, pepper, relish, and fish sauce. Dairy: milk, cheese, butter, many types of yogurt Cereals: rice, quinoa, and amaranth
Barley and Malt[9]	Beer, malt,[9] malt syrup,[11] malt extract,[10] cereal,[11] and orzo[8]	Almonds, peanuts, pistachios, and cashews
Rye,[7] triticale (a cross between wheat grain and rye)	Cereal[11]	Others: teff, millet, sorghum, arrowroot, yucca, potatoes, tapioca, and soy and many types of ice cream, grits, corn, beans. Special gluten-free foods prepared with rice flour, sorghum flour, or coconut flour
Semolina[11]	Pasta[11]	
Farina[11]	Pasta[11]	

Table 2. Types and symptoms of celiac disease.

TYPES OF CELIAC DISEASE	SYMPTOMS	SMALL BOWEL VILLOUS ATROPHY	POSITIVE SEROLOGIC MARKERS
Classic celiac disease	Chronic diarrhea and weight loss[8]	Yes	Yes
Nonclassic celiac disease	Anemia, disease in bones, infertility, adverse outcomes in pregnancy, lymphoma, and liver disease. In addition, individuals with an atypical celiac disease may have symptoms including reflux, vomiting, bloating, abdominal pain, and constipation[9]	Yes	Yes
Silent celiac disease	Characterized by an asymptomatic state that can last for years[12,13]	No	Yes
Potential or latent celiac disease	Positive antibody screen but not small bowel villous atrophy. These individuals could develop villous atrophy if they continue with a gluten diet[14]	No	Yes
Refractory sprue/celiac disease	Characterized by villous atrophy and a persistent intestinal inflammation and other symptoms such as diarrhea, whereas the patient keeps a strict gluten-free diet[15]	Yes	Yes

Types of CDs

Five types of CDs have been identified according to small bowel villous atrophy and positive serologic markers in patients. These include classic, nonclassic, silent, potential CD, and refractory sprue (Table 2). The classic symptomatic CD is characterized by common symptoms of malabsorption and occurs in children between 6 and 24 months of age.[8] Nonclassic symptomatic CD includes a variety of symptoms such as iron deficiency anemia. The anemia occurs due to malabsorption of iron and folate in the jejunum. Nonclassic CD is more common than classic CD.[9] Silent CD has no symptoms. However, the detection of positive celiac-associated antibodies, HLA-DQ2/DQ8, and atrophy of the villi in the small bowel biopsy must be tested. Patients with this type of CD are identified via affected family members or via serum markers belonging to one of the risk groups.[10]

Potential CD has a normal small bowel biopsy and positive serum markers. The continuous ingestion of gluten can result in villous atrophy. Refractory sprue/CD is divided into 2 groups: primary refractory sprue (when the patients do not have a good response to a gluten-free diet) and secondary refractory sprue (when patients respond well to a gluten-free diet but subsequently relapse). These 5 types of CDs establish the celiac iceberg, which represents the complexity of the disease that, in some cases, remains undiagnosed[8] (Figure 1).

Gastrointestinal and Nongastrointestinal Manifestations

Celiac disease is characterized by a high level of variability in patients and their clinical manifestations. The most characteristic symptoms are diarrhea, steatorrhea, extreme

lethargy, bloating, edema, and atrophy of the villi of the small bowel.[2] Other symptoms may occur in a lower percentage of individuals such as anemia, bone diseases, weight loss, and abdominal pain.[8] Table 3 presents other symptoms besides the gastrointestinal findings including certain atypical symptoms and their association with other diseases.[11]


Figure 1. Graphical representation of the types of celiac disease "celiac iceberg." The tip of the iceberg represents symptomatic cases, whereas the rest of the iceberg are silent cases and latent cases that are undiagnosed.[8]

From 6 to 24 months of age, children present symptoms such as impaired growth, abdominal distention, abnormal stools, fatigue, problems with the nervous system and musculoskeletal systems, as well as dermatological, hematological, endocrinologists, oncological, neurological, and pulmonary findings.[10,16] Regarding clinical manifestations, classic CD is more common in children, whereas silent CD is more common in adults.[17] In addition, adults have a much higher delay in diagnosis (10 ± 9 years) compared with children (1 ± 2 years). Adults are frequently associated with other autoimmune diseases. There is not a significant difference between children and adults in terms of genetic biomarkers.[18]

Infertility is also common in adult women. Studies have shown that 2.65% of women with infertility are CD-positive via endomysial antibody (EMA) test.[20,21] Singh et al[22] confirmed that CD is more prevalent in women with all types of infertility than in the general population. According to Lasa et al,[23] when infertility is unknown, it is advisable to conduct CD tests. A gluten-free diet could improve the likelihood of conception. Men could also be affected with teratozoospermia and asthenozoospermia.[24] In addition, children of male patients with CD can have a shorter gestational age and lower birthweight.[15]

Furthermore, CD is associated with autoimmune diseases— mainly with type 1 diabetes mellitus that occurs in 3.5% to 5%

Table 3. Clinical manifestations of celiac disease and their association with other diseases.

TYPICAL SYMPTOMS	ATYPICAL SYMPTOMS	ASSOCIATED GENETIC DISEASES	ASSOCIATED AUTOIMMUNE DISEASES	PSYCHIATRIC DISEASES	REFERENCES
Abdominal distention Chronic diarrhea Bloating	NR	NR	NR	NR	Dewar and Ciclitira[2]
Malabsorption symptoms from mild to severe Lethargy Vitamin deficiency	NR	NR	NR	NR	Taylor et al[8]
Stunting Anorexia Muscle loss Poor appetite	Osteoporosis/osteopenia Cerebellar ataxia Epilepsy Dermatitis herpetiformis Dental enamel hypoplasia Delayed puberty Infertility Recurrent and spontaneous abortions Recurrent aphthous stomatitis	Diabetes mellitus Autoimmune thyroid disease Myasthenia gravis	Down syndrome IgA deficiency Turner syndrome William syndrome	Autism	Admou et al[11]
Behavioral changes (depression and irritability)	Liver disorders (hypertransaminasemia)	Sjögren's syndrome Autoimmune hepatitis Psoriasis	Addison's disease Cardiomyopathy	Schizophrenic symptoms Affective disorders Social phobia Extreme depression	Celiloglu et al[10]
Nausea and vomiting Lactose intolerance	Constipation and headaches Anemia Short height	NR	NR	NR	Murray et al[19]

Abbreviation: NR, not reported.

Table 4. Diseases with increased risk of CD.

DISEASE (RISK GROUP)	RISK ASSOCIATED WITH CD, %
Type 1 diabetes mellitus	1–16
Down syndrome	5–12
First-degree relative	4–12
William syndrome	3–10
Turner syndrome	3–10
Thyroiditis	3–5
Selective IgA deficiency	2–10
Sjögren's syndrome and other diseases	3–5

Abbreviation: CD, celiac disease.

of patients with CD. Another prevalent condition is hypothyroidism, which is 10-fold more common in celiac patients. Liver diseases such as autoimmune hepatitis and sclerosing cholangitis transaminitis are common. Finally, Crohn disease, alopecia areata, Sjögren's syndrome, hypopituitarism, ulcerative colitis, scleroderma, Addison's disease, dermatomyositis microscopic colitis, systemic lupus, psoriasis, erythematosus, and hypoparathyroidism are also associated with CD.[25] Table 4 summarizes the risk of developing each disease depending on health conditions.[7,8]

Genetics of CD

The pathogenesis of CD remains incompletely understood, but adaptive and innate immune responses have major roles. Genetics is a contributing factor to CD disease susceptibility, but environmental factors such as gluten are also determinant.[26,27] The HLA complex is mainly related to CD, and it consists of 47 Mb on chromosome 6p21. It contains approximately 200 genes, of which more than half have an immune purpose. The main function is the presentation of exogenous peptide antigens to the helper T cells.[28] In addition, many genetic linkage analyses have identified susceptible loci in certain chromosomes, ie, in chromosomes 2, 5, 6, 9, 15, and 9. This reveals the multifactorial complexity of CD that is associated with the presence of the HLA heterodimers.[29,30]

The HLA-DQ2*5 molecule is encoded by DQA1*05:01 and DQB1*02:01 alleles in *cis*-configuration in the DR3 haplotype. In general, up to 95% of patients with CD are positive to HLA-DQ2 (DQA1*0501/DQB1*0201), and the remaining 5% are positive to HLA-DQ8 (HLA-DQB1*0302) haplotypes.[31] HLA-DQ2/DQ8 common haplotypes have been shown to elevate disease risk by 6-fold. However, HLA status alone cannot initiate or promote the development of CD in individuals.[32] Moreover, HLA-DQ2 or HLA-DQ8 is positive in 40% of Europeans, but only 3% of them develop CD.[26] The CD-related HLA DQ antigens (DQ2) are present in 5% to 10% of Chinese and sub-Saharan Africans versus 5% to 20% in

Western Europeans. The DQ8 is positive in 5% to 10% of English, Tunisians, and Iranians and in <5% of Eastern Europeans, Americans, and Asians.[33]

Recent studies have characterized CD as highly heritable. However, the development of the disease is also related to environmental factors.[34] Moreover, the frequency of the disease in first-degree relatives is high, but inheritance has not yet been completely confirmed. It is known that the HLA genes have moderate impact on CD heritability and have Mendelian inheritance with incomplete penetrance.[8,35]

The recent fine mapping and genome-wide association studies (GWAS) have identified up to 57 non-HLA CD susceptibility single-nucleotide polymorphisms (SNPs), most of which are noncoding variants lacking any functional annotation.[26] Therefore, rather than showing these unknown variants, we focused on Banaganapalli et al,[27] who adopted a multidimensional computational approach for uncovering the plausible mechanisms through which these GWAS SNPs are connected to CD pathogenesis. The functional annotations of 57 CD lead variants and their strongly linked 1008 variants was conducted with the 1000 genome project data of Central European Populations (CEU). The *LD* variant consists of 939 SNPs, 28 insertions, and 41 deletions. At the initial phase, they identified that 25 (43.85%) out of 57 CD-SNPs lie in evolutionarily constrained genetic element regions.

In the follow-up phases, the authors used computational algorithms (CADD, GWAVA, and FATHMM) and deleterious intensity measurements to discover that 42 (3.94%) out of 1065 variants (57 CD lead and 1008-linked SNPs; r2 ≥ 0.8) are differentially deleterious or possibly deleterious in nature to CD. Data analysis of deleterious variants revealed that 12 allelic variants (3 rank I + 9 rank II SNPs) localized to 7 genes have significant differential expression in nonimmune cell sources. Five SNPs (rs34505903, rs6441961, rs6441962, rs6441972, and rs6771900) showed significant expression quantitative trait loci (eQTL) for CCR2 gene in skin tissue. The significant eQTLs were also observed for 2 rank II SNPs (rs10797440 and rs4648562) for MMEL1 gene in blood. The other genes with significant eQTL expression were PLEK (rs3816281—blood), UBE2L3 (rs11089620—blood), ELMO1 (rs60600003 gene—intestinal tissue), and LMAN1L (rs4886619 gene—esophagus tissue).[27]

Deleterious SNPs of CCR2 gene influences its expression levels and may also elicit a cascade of T cell–mediated immunologic events leading to intestinal gluten intolerance in genetically susceptible individuals (Table 5). This study demonstrates the utility of integrated in silico analysis of annotations, gene expression, and pathways in prioritizing the potential complex disease variants from large-scale open-source genomic data.[27]

Prevalence

Studies of CD around the world are shown in Table 6. Celiac disease is almost exclusively seen in European populations. Several serological studies of people from America, Australia,

Table 5. Multiple functional annotations and prediction analysis of the 12 CD susceptibility SNPs revealed by the eQTL analysis.

SNP ID	CHROMOSOME	GENE SYMBOL	DELETERIOUS CATEGORY	EQTL EXPRESSION ANALYSIS, *P* VALUE
rs2984920	1	RGS1	Rank 1	1.60×10^{-17}
rs10797440	1	MMEL1	Rank 2	5.40×10^{-12}
rs4648562	1	MMEL1	Rank 2	5.70×10^{-14}
rs3816281	2	PLEK	Rank 2	$1.4 \times 10^{-0.6}$
rs34505903	3	CCR2	Rank 1	$5.90 \times 10^{-0.8}$
rs6771900	3	CCR2	Rank 2	$6.30 \times 10^{-0.8}$
rs6441961	3	CCR2	Rank 2	$6.30 \times 10^{-0.8}$
rs6441962	3	CCR2	Rank 2	$6.30 \times 10^{-0.8}$
rs6441972	3	CCR2	Rank 1	$8.10 \times 10^{-0.9}$
rs60600003	7	ELMO1	Rank 2	$2.7 \times 10^{-0.7}$
rs4886619	15	LMAN1L	Rank 2	1.00×10^{-11}

Abbreviations: CD, celiac disease; eQTL, expression quantitative trait loci; SNP, single-nucleotide polymorphism.
Rank 1: deleterious variants; rank 2: possibly deleterious variants.

Asia, and Africa have shown that the prevalence in these regions is 0.5% to 1%.[1,36] Thus, it was found that CD is a worldwide condition and is probably the most common disorder related to food intolerance.[37,38]

Fasano et al[36] studied a North American population and found that the prevalence of CD is similar among different age groups (children, adolescents, adults, and the elderly) (0.8%). Risk populations include patients with CD, symptomatic patients, and people with type 1 diabetes mellitus, infertility, osteoporosis, anemia, short stature, arthritis, and Down syndrome. These have the highest prevalence (1.2%-4.8%).[36] However, only 17% of CD individuals have been diagnosed.[8]

Data on the prevalence of CD are scarce in Latin America. It has been estimated that Argentina, Brazil, and Chile have a prevalence of 0.6% in adults, 0.15% in blood donors, and 4.76% in risk populations.[41–43] Moreover, in Central America (Cuba) in 1981, cases of children with CD were reported with a prevalence of 2.3%.[44]

In Europe, CD has been extensively studied along with its prevalence. In general, the prevalence in Europe is 1%, but this varies from country to country. In subjects aged 30 to 64 years, the prevalence is 2.4% in Finland and Sweden, 0.3% in Germany, and 0.7% in Italy.[45]

Although CD seems absent in Asian populations, approximately 3 to 10 cases remain undiagnosed. Other studies have shown that the prevalence of CD is high. In India (Punjab), the prevalence in children is 0.3%.[58] In the northern part of India, the general prevalence is 1.04%.[59] In other locations in Asia, the prevalence of CD remains unknown. Turkey, Iran, Syria, and Israel have values between 0.2% and 2%.[60–63] In Japanese and Chinese populations, CD is believed to be practically nonexistent. However, there are studies in adult descendants of Chinese and Japanese families who migrated to Canada showing positive CD results.[73] In fact, a sample of 62 Chinese patients with chronic diarrhea showed that 4 were diagnosed with CD suggesting that the disease may be more common than it was believed to be by Asians.[64] According to Cummis and Roberts-Thomson,[65] the prevalence in Japan is 0.005%.

In North Africa, a high incidence of CD has been found (0.25%-5.6%) in the general population. These data are very close to those reported in European countries.[62]

In addition, a study on Saharawi children was conducted to detect CD using antiendomysial and anti-transglutaminase (anti-tTG) tests. As a result, a prevalence of 5% to 6% was obtained.[45] Although the reason for the high prevalence in these regions is not clear, the genetic background could be a link. Moreover, it is believed that this high prevalence is an evolutionary advantage to obtain fewer differentiated enterocytes necessary for the accession of microorganisms in the duodenum. Therefore, CD gives a selective advantage to protect individuals from gastrointestinal infections and parasites such as *Giardia lamblia* or *Vibrio cholerae*.[68]

Three studies of CD in Oceania have been reported. The first was done in 2000 in Christchurch, New Zealand, resulting in a 1.2% general prevalence.[71] The second one was conducted in 2001 in West Australia with a prevalence of 0.23%. The third study was a screening using anti-tissue transglutaminase (tTG) antibody assays in 3011 subjects showing a prevalence of 0.56% to 0.96%.[72]

According to Clot and Babron, there is a genetic predisposition in certain individuals, which increases the prevalence of the disease. For example, between monozygotic twins, there is

Table 6. Worldwide celiac disease prevalence.

COUNTRY	PATIENTS ANALYZED	PREVALENCE, %	TYPE OF SAMPLE	DIAGNOSTIC METHOD	REFERENCES
America					
USA	8631 (adults)	2.55	Blood	ELISA antibody measurement (IgA, IgG) and genetic test (HLA-DQ2/8)	Fasano et al[36]
	2845 (adult population at risk)	0.95	Blood	ELISA antibody measurement (IgA, IgG) and genetic test (HLA-DQ2/8)	Fasano et al[36]
	7798 (from 6 y to adults)	0.7	Blood	ELISA IgA tTG	Rubio-Tapia et al[39]
Canada	233 (children with type 1 diabetes)	7.7	Blood	IgA-EMA, and IgA tTG	Gillett et al[40]
Argentina	2000 (16 to 79 y)	0.6	Blood	AGA, EMA	Gomez et al[41]
Brazil	2045 (blood donors)	1.15	Blood	ELISA IgA-EMA, IgG-AGA	Gandolfi et al[42]
Chile	188 (relatives of celiac patients)	4.76	Blood	ELISA EMA, HLA	Araya et al[43]
Cuba	519 (children 3mo-14y)	2.3	Biopsy	Microscopy	Rabassa et al[44]
Europe					
Total	29212 (adults and children)	1	Blood	tTG and EMA	Mustalahti et al[45]
Italy	17201 (students 6-15y)	0.5	Blood and biopsy	IgG-AGA and IgA-AGA and microscopy	Catassi et al[46]
Estonia	805 (children)	1.1	Blood	ELISA for AGA and R1-type antireticulin antibodies	Uibo et al[47]
Finland	3654 (children 7-16y)	1	Blood and biopsy	EMA, tTG, and microscopy	Mäki et al[48]
Germany	2157 (older than 18y)	0.37 Most common in women 0.45% than men 0.19%	Blood and biopsy	IgA tTG, EMA and AGA, and microscopy	Kratzer et al[49]
Hungary	427 (children 3-6y)	1.2	Blood	IgA- and IgG- EMA using monkey esophagus and human jejunum as substrates	Korponay-Szabó et al[50]
Holland	50760	0.35	Blood	Serologic screening and HLA typing	Schweizer et al[51]
Romania	2436 (older than 16y)	2.22	Biopsy	Upper endoscopy and microscopy	Dobru et al[52]
Switzerland	1450 (11-18y)	0.75	Blood	IgA titers, EMA, IgA titers EMA and anti-human tTG IgA (hTTG) titers	Rutz et al[53]
Spain-Madrid	3378 (10-12y)	0.3-0.45	Blood	Total serum IgA, IgA-EMA and IgG-AGA	Cilleruelo Pascual et al[54]
North Spain	1170	0.26	Blood	IgA and IgG-AGA and IgA EMA	Riestra et al[55]
Portugal	536 (children 14±6mo)	0.74	Blood and biopsy	Total IgA, anti-tTG, EMA, and microscopy	Antunes et al[56]
Ireland	63901 children	0.33	Biopsy	Microscopy Crosby capsule	Mylotte et al[57]

Table 6. (Continued)

COUNTRY	PATIENTS ANALYZED	PREVALENCE, %	TYPE OF SAMPLE	DIAGNOSTIC METHOD	REFERENCES
Asia					
North India (Punjab)	4347 children (3-17 y)	0.3	Blood	Anti-tTG by indirect solid-phase immunometric assay (ELISA)	Sood et al[58]
North India (Delhi)	10488	1.04	Blood and biopsy	Anti-tTG	Makharia et al[59]
Turkey	906 (20-59y)	1	Blood and biopsy	Anti-tTG IgA and serum IgA and microscopy	Gursoy et al[60]
Iran	2799 (18-66y)	0.96	Blood and biopsy	IgA anti-tTG and IgA anti-EMA and microscopy	Akbari et al[61]
Syria	—	1.6	—	—	Gujral et al[62]
Israel	1571 (blood donors)	0.64	Blood and biopsy	Serologic test and microscopy	Shamir et al[63]
China	62	6.45	Biopsy	Capsule endoscopy and microscopy	Jiang et al[64]
Japan	—	<0.005	—	—	Cummins and Roberts-Thomson[65]
Malaysia	562 (18-30y)	1.25	Blood	AGA IgA/IgG and tTG IgA/IgG	Yap et al[66]
Africa					
Egypt	1500 children	0.53	Blood and biopsy	tTG, IgA-EMA, and microscopy	Abu-Zekry et al[67]
Algeria	497 (insulin-dependent diabetes mellitus patients)	16.4	Blood	Serological markers	Mustalahti et al[45]
Algeria—Saharawi people	989 (Saharawi children)	5-6	Blood	EMA and anti-tTG	Catassi et al[68]
Tunisia	6286 (9.7±3y)	0.64	Blood and biopsy	IgA tTG, EMA IgA and microscopy	Ben Hariz et al[69]
Unite Arab Emirates	1197(older than 16y)	1.17 (13 women and 1 man, 14:1197)	Blood	tTG IgA and EMA IgA	Abu-Zeid et al[70]
Oceania					
New Zealand	1064	1.2	Blood and biopsy	EMA and microscopy	Cook et al[71]
Perth, Australia	3011	0.56	Blood and biopsy	IgA and IgG, anti-tTG antibodies, HLA-DQ2/8 haplotyping, and microscopy	Chin et al[72]

Abbreviations: EMA, Anti-endomysial antibody; AGA, antigliadin antibody; ELISA, enzyme-linked immunosorbent assay; IgA, immunoglobulin A; IgG, immunoglobulin G; tTG, anti-tissue transglutaminase.

a high rate (70%), whereas among first-grade relatives the value is 10% to 15%; in dizygotic twins, it is 30%.[32]

Diagnostics

It is important to mention that clinical manifestations are not sufficient for a true diagnosis. Rather, a combination of several complementary studies such as clinical, hematological, serological, genetics, results from biopsies of the duodenum, and the response to a gluten-free diet is required. In addition, other groups are more susceptible to developing CD. These include first-degree relatives of patients who have already been diagnosed, patients with Down syndrome, type 1 diabetes mellitus, autoimmune thyroiditis, selective IgA deficit, digestive diseases, autoimmune diseases, neurological and psychiatric disorders, or other conditions such as fibromyalgia and Turner syndrome.[74]

However, there are several strategies for diagnosis. The typical diagnosis includes a blood count to determine clotting times, which in positive patients can present alterations. A complete biochemistry panel includes ferric levels, serum transferrin levels, transferrin saturation, and a liver test.[75] Symptoms that are related to CD, other associated diseases, and the risk groups should be studied for a better diagnostic strategy. Symptomatic patients differ in their symptoms according to their age; ie, children show irritability, diarrhea, abdominal pain, decay, lack of appetite, malnutrition, anemia, and muscular hypotrophy.[74] In adult patients, digestive problems are usually not seen; however, other symptoms such as abdominal pain, delayed menarche or irregular menstrual cycles, iron deficiency anemia, short height, and muscular weakness have been reported. Youth and adolescents usually present dermatitis herpetiformis.[75]

Clinical diagnois: antibody testing

The diagnosis of CD from serological tests changed the perspective of the disease because its impact was much greater than expected. Serological tests can determine the condition in most classical symptoms.[74] Different serological markers are used. The most widely used are the AGA and immunoglobulins (IgA and IgG) acting against α-gliadin antigens. Other antibodies include tissue transglutaminase (tTG), antiendomysium (EMA) and gliadin peptides.[75]

Table 7 shows the specificity and sensibility of the antibodies used in the diagnosis of CD. On the other hand, EMA have a higher efficiency (95%).[74] Nevertheless, some problems have been identified with this technique. At the end of the 20th century, tissue transglutaminase tTG auto-antigens reacting against the EMA was described. The tTG has been widely used due to its determination by enzyme-linked immunosorbent assay with ≥90% efficiency. However, the sensitivity and accuracy of the tTG depend specifically on the intensity of the duodenal lesion.[75]

When patients follow a gluten-free diet, antibodies are no longer present in the blood because their production is not

Table 7. Sensitivity and specificity of serum antibodies.[8]

ANTIBODIES	SENSITIVITY, %	SPECIFICITY, %
Antigliadin	75–90	82–95
Antiendomysial	85–98	97–100
Tissue transglutaminase	90–98	94–97
IgA-DGP	75–78	95–100
IgG-DGP	65–71	95–85

Abbreviation: DGP, deamidated gliadin peptide.

needed and their diagnosis is not effective. In this case, individuals may consume food containing gluten for at least 2 weeks before the antibody test.[76]

Histologic diagnosis

Duodenal endoscopy findings can be helpful for the diagnosis of CD. One of them is the "pattern in mosaic," characterized by a reduction or disappearance of the folds of Kerckring. The other refers to the "scalloped pattern" describing the circular folds of the duodenum that acquire a toothlike configuration. Currently, diagnosis through Marsh classification from an upper endoscopy in adults has been shown to be the most widely used technique. Marsh allows the identification of the entire spectrum of histologic lesions (Table 8). However, a combination with antibody testing may be required in some cases. This technique could fail to detect histologic changes when the patient is under a gluten-free diet or there are patchy mucosal lesions, peptic changes, incorrect orientation of the slide during the microscope analysis, a limited number of samples taken, or latent CD.[8]

In Marsh I cases (lymphocytic enteritis), either a subsequent diagnosis with hematoxylin-eosin staining or immunohistochemical techniques with monoclonal antibodies are recommended because it can cover the same symptomatology of patients with villous atrophy.[78] Up to 95% of cases diagnosed with CD during childhood can have a complete recovery of the intestinal mucosa within 2 years after starting a gluten-free diet.[79] However, in adults, the recovery rate of the mucosa is less effective and requires more than 12 months of a strict gluten-free diet.[76] However, a minority of patients without symptoms but with persistent atrophy of the villi of the mucosa may develop refractory CD that opens the possibility to other complications over time.[80]

Genetic testing

Currently, there are genetic markers for the diagnosis of CD based on the identification of alleles coding for HLA-DQA1, HLA-DQ2, HLA-DQB1, or HLA-DQ8. The presence of HLA alleles could determine the susceptibility to CD.[8] The HLA-DQA1 codes for the α chain of HLA heterodimers, whereas HLA-DQB1 codes the β chain. Approximately 90%

Table 8. Modified Marsh classification.[77]

			JEJUNUM/100 ENTEROCYTES	DUODENUM/100 ENTEROCYTES
Marsh 0	Preinfiltrative mucosa	CD unlikely	<40	<30
Marsh I	Lymphocytic enteritis	Dermatitis herpetiformis, relatives of patients with CD	>40	>30
Marsh II	Crypt hyperplasia	Rare Dermatitis herpetiformis	>40	>30
Marsh IIIa	Partial villous atrophy	CD symptomatic	>40	>30
Marsh IIIb	Subtotal villous atrophy		>40	>30
Marsh IIIc	Total villous atrophy		>40	>30

Abbreviation: CD, celiac disease.

of the people with CD express the HLA-DQ2 heterodimer, which compromises 2 gene variants: HLA-DQA1*0501/*0505 and HLA-DQB1*0201/*020*. Patients express only 1 of the variants—not both. The HLA-DQ8 heterodimer is expressed in 5% to 10% of the cases.[74,81]

However, there is evidence that non-*HLA* genes are associated with CD susceptibility. van Heel et al[28] affirms that *HLA* genes contribute to 30% to the development of CD and non-*HLA* to 70% in identical twins.

Genetic testing is recommended for patients who have a well-founded clinical suspicion and present anomalies in their duodenal histologic findings. An individual is considered genetically predisposed to CD if DQ2 and/or DQ8 are positive.[8]

A definitive diagnosis for CD could be confirmed when the person has a positive result on biopsy and has a clinical and histologic improvement after a gluten-free diet. In cases of refractory sprue suspicion, imaging, immunohistochemical, and TCR gene rearrangements as well as the evaluation of T-cell lymphoma studies should be performed.[25]

New and future diagnostic strategies

Because the prevalence of CD has increased in the last years, early diagnosis is imperative for risk families and undiagnosed patients.[82] To achieve this, new diagnostic methods and treatments for CD are being tested including salivary diagnostic tests, gene expression panels, reduced-gluten grains, oral enzyme therapeutics, and DQ2 blockers.[83,84]

There is a possibility of diagnosing CD through a saliva sample. Rujner et al[85] presented results regarding the sensitivity of salivary tests IgA-EMA (antiendomysium) and IgG-AGA (antigliadin). In 2011, a CD screening was done using saliva samples from Italian children. Anti-tTG and immunoglobulin (IgA) assays were performed using fluid-phase radioimmunoprecipitation.[86]

Capsule endoscopy is a recent and less aggressive method that scans the entire digestive tract. With this methodology, anomalies and histologic changes in the duodenal field could be analyzed. The capsule endoscopy represents an effective technique for the diagnosis of CD and other diseases associated with recurrent gastrointestinal hemorrhage and malignant tumors in the bowel, but it cannot obtain biopsies.[75]

Chromoendoscopy offers high specificity and sensitivity that determines the villous changes using specific dyes.[82] However, this technique needs a magnification endoscopy to show improved yields in CD gastroscopy. In addition, narrow-band imaging uses filtered light that is absorbed by hemoglobin to show intestinal mucosa vascular organization. This could detect partial damages in patients with CD.[87] A new diagnostic technique is the biopsy-based organ culture. Recent research has shown that celiac antibodies could be detected in small-intestinal organ cultures of patients with CD.[88] However, these techniques are laborious, time-consuming, and require special skilled and experienced personnel.

Future biomarkers candidates

Galatola et al[82] stated that CD could be predicted using small panels of genes including KIAA, TAGAP, and SH2B3 9 months before clinical or serological signs. Trynka et al[89] estimate 40 known loci that are related to the development of CD. In addition, Lie et al[90] showed that there are genes involved in pathogenesis of both CD and type 1 diabetes that are located within or near the HLA.

Other genes unrelated to the HLA complex have a relationship with the development of CD. These include *Myoxin IX*, which increases the risk of developing CD 2.3-fold due to the cytoskeleton remodeling and cell permeability in the duodenal wall epithelium functions.[8]

IL2-IL21 is another non–*HLA*-related gene region associated with susceptibility to CD. This explains the 3% to 4% of inheritance of the disease. However, near this region, related SNPs associated with the CD are found and demonstrate the genetic relationship of the region.[91]

Genes coding for signaling molecules that play a role in the secondary activation of T lymphocytes have also been correlated to the development of CD in Finnish families. These include *CTLA4* (cytotoxic T lymphocyte associated), *CD28*, and *ICOS* (inducible co-stimulator). They are all located on

Table 9. Major genes related to CD.

CD-RELATED GENES	FUNCTION	REFERENCES
HLA-DQA1	Encoding the α chain of HLA heterodimers	Taylor et al[8]
HLA-DQB1		
Myoxin IXB	Reshapes the cytoskeleton and tight junctions to increase cell permeability	
IL2-IL21	Activation and proliferation of T cells	Hunt et al[94] and Husby et al[100]
CTLA4	Signaling for T-lymphocyte activation	Haimila et al[92]
CD28		
ICOS0LG		
SH2B3	NOD2 recognition pathway activation	Guo et al[93]
IL10	Intervenes in severe inflammatory lesion of the small intestine mucosa	Barisani et al[95]
CCR3	Gene encoding chemokine receptors (immune function)	Hunt et al[94]
IL18RAP	Receptors for the IL-18 protein	
RGS1	Regulator of G protein signaling 1	
IL12A	Encodes the IL12p35 subunit, this molecule has activities on T cells and natural killer cells	
TAGAP	T-cell activation GTPase–activating protein	
MICA and MICB	Hypersensitive innate immune response	Lopez-Vazquez and colleagues[96,101]

Abbreviations: CD, celiac disease; GTPase, guanosine triphosphatase.

chromosome 2q33. However, according to Haimila et al,[92] the link to *CTLA4* is still under study.

In a study of 12 000 patients with CD GWAS studies, CD susceptibility is related to 43 loci (including HLA locus). Moreover, SNPs in the non-HLA loci represent approximately 15% of the disease risk. Interestingly, most of the CD-associated SNPs do not imply protein changes. The immune response of CD is also determined by *SH2B3, CCR3, IL18RAP, RGS1, IL12A,* and *TAGAP SNPs*. The rs3184504 in the *SH2B3* gene has specifically shown disease susceptibility. The *IL10* allele variants are related to CD due to the reduction in the production of anti-inflammatory cytokines involved in the response of severe inflammatory lesions caused in the early stages of the disease.[8,93–95]

In addition, there is a positive relation between CD and *MICA* SNPs. MICA-A5 transmembrane SNP is associated with atypical CD. Lopez-Vazquez et al[96] demonstrated high expression of this gene in biopsies. Similarly, the allele MICB0106 is significantly associated with the disease.[36] Therefore, *MICA* and *MICB* molecules are overexpressed in CD[7]; CD major susceptibility genes can be found in Table 9. Finally, *HLA* genes are highly polymorphic with more than 7500 common SNPs. Thus, the genotyping of SNPs could present an efficient diagnosis of CD risk groups and patients.[97] However, there are differences between worldwide populations.[37,98,99]

We suggest considering Banaganapalli et al[27] because the presence of any of these 12 SNPs is deleterious. Other biomarker candidates are being studied for CD diagnosis including serum intestinal fatty acid–binding protein, CYP3A4-catalyzed simvastatin metabolism, and gluten-reactive CD4+ T cells in the blood.[97] Intestinal fatty acid–binding protein is presented in the epithelial cells of the intestine and released into blood on mucosal injury and presented in patients with CD.[102] CYP3A4 metabolizes simvastatin—a cholesterol-lowering drug. In patients with CD, CYP3A4 expression and activity are reduced.[103] Finally, gluten-reactive CD4+ T cells were found in higher concentrations in the circulation of patients with CD who are untreated and under a gluten-free diet.

Treatment

The only treatment that works with excellent results is a permanent gluten-free diet. In children, this treatment eliminates gastrointestinal symptoms, stabilizes nutritional measures, improves growth, and stabilizes weight and hematological/biochemical parameters. However, sticking to a gluten-free diet is very difficult because many products that claim to be gluten-free actually have traces of gluten. It has been shown that small amounts of gluten are sufficient to cause changes in the intestinal mucosa.[8]

Therapeutic Approaches

In low-income countries, the dietary treatment could be expensive and difficult to achieve. Consequently, new treatments are being investigated.[97] This includes oral enzyme therapeutics. The objective of this strategy is to reduce the amount of gluten

that reaches the small intestine to prevent the immune response. The human digestive system lacks PEP enzymes capable of degrading peptides found in gluten. The problem with this strategy is the large amount of enzymes needed to cover a gluten detoxification of a daily intake of 20 g. Furthermore, the stomach environment could decrease enzyme function.[83] In contrast, minimizing gluten absorption can use HMW polymers with affinity for gluten binding. Thus, gluten is not absorbed by the epithelium and does not exert toxicity.[104]

Alternatively, de-sensitization treatment involves repeatedly dosing selected gliadin immunogenic peptides of wheat, barley, and rye that inhibit the proliferation of T cells and expression of pro-inflammatory cytokines. As a result, gluten tolerance is recovered.[84] Finally, one way to prevent the interaction with gluten is blocking the synergy of HLA molecules with gluten peptides—this requires high affinity blockers.[19]

However, proteins present in gluten have been investigated, and there are several strategies to remove CD activator proteins in gluten-containing grains. One of these is via genetic manipulation and selective breeding. However, one concern is that the desirable features of flour will be lost.[83]

Finally, a disease-modifying therapeutic approach for CD is being developed. This intradermal therapeutic vaccine claims to return a HLA-DQ2.5-positive patient to a normal diet with peptides that trigger a pro-inflammatory response and stop the immune defensive activity to gluten antigens.[105] However, this method is under investigation.

Patients could also have the symptoms of the disease despite a gluten-free diet. In this case, food cross-contamination in commercial products such as canned food, millet, sorghum, frozen foods, ham, bacon, and meat cured products should be tested.[106,107] The Alimentarius Codex has established a limit of 20 ppm (mg/kg) of gluten in food to categorize food as gluten free.[108] However, Collin et al estimated that the residual amount of gluten suitable for celiac patient consumption was 100 ppm. Moreover, the daily flour intake for long-term mucosa recovery was 80 g. In conclusion, the 100 ppm contained in 830 mg of gluten was shown to be safe for celiac patients.[109]

There are also over-the-counter (OTC) medications with active and inactive ingredients, but consumers do not always have access to such information. It is important to note that both starch and hydrolyzed starch, as well as wheat, are common ingredients in OTC medicines. In addition, inactive ingredients and their sources are usually variable between original and generic drugs.[110]

Morbidity and Mortality
The mortality of CD increases from 1.9 to 3.8 times due to the development of malignancies such as lymphomas, mouth and pharynx squamous cell carcinomas, and small intestine adenocarcinoma. However, patients who follow a strict gluten-free diet significantly reduced the occurrence of these conditions.[25]

Ludvigsson et al found an increased mortality and latent CD in their study. The mortality rate found was 10.4 per thousand people per year, whereas in the latent CD, it was 6.7. Thus,

they concluded that the risk of death from CD has a relatively high value.[111] According to Peters et al, cardiovascular disease is the leading cause with 39.4% in patients with CD, followed by malignant neoplasms with 19.4%, digestive diseases with 12.1%, and respiratory diseases with 9.8%.[112]

Finally, although CD is more common than thought, its symptoms can easily be confused with other diseases or it can be misdiagnosed. A variety of genes are involved in the predisposition to this disorder. Therefore, further studies are needed to identify a more reliable, effective, and less invasive diagnostic method. The prevalence of the disease varies from country to country but is seen in people of different ethnicities.[113]

Author Contributions
Research: CS; Contributed to the writing of the manuscript: CS and JMG; Jointly developed the structure and arguments for the paper: CS and JMG; Made a critical revisions and approved final version: CP. All authors reviewed and approved of the final manuscript.

REFERENCES
1. Cataldo F, Montalto G. Celiac disease in the developing countries: a new and challenging public health problem. *World J Gastroenterol.* 2007;13:2153–2159.
2. Dewar DH, Ciclitira PJ. Clinical features and diagnosis of celiac disease. *Gastroenterology.* 2005;128:S19–S24.
3. Paulley JW, Fairweather FA, Leeming A. Post-gastrectomy steatorrhoea and patchy jejunal atrophy. *Lancet.* 1957;272:406–407.
4. Henry R, Kettlewell P. *Cereal grain quality.* Berlin, Germany: Springer Science & Business Media; 2012.
5. Wieser H. Chemistry of gluten proteins. *Food Microbiol.* 2007;24:115–119.
6. Kagnoff MF. Celiac disease: pathogenesis of a model immunogenetic disease. *J Clin Invest.* 2007;117(1):41–49.
7. Torres Odio S, Martínez Córdova Z. Base genética de la enfermedad celiaca en el diagnóstico. Genetic base of celiac diseases in diagnosis. *Rev Cubana Med Gen Integr.* 2012;51:170–182.
8. Taylor AK, Lebwohl B, Snyder CL, Green PHR. Celiac disease. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. *GeneReviews.* Seattle, WA: University of Washington; 2015.
9. Allué IP, Pediátrica N. *Enfermedad celíaca presente y futuro.* Madrid, España: Ergon; 2013.
10. Celiloglu C, Karabiber H, Selimoglu MA. Atypical presentations of celiac disease. *Turk J Pediatr.* 2011;53:241–249.
11. Admou B, Essaadouni L, Krati K, et al. Atypical celiac disease: from recognizing to managing. *Gastroenterol Res Pract.* 2012;2012:9.
12. Miranda Díaz M, Alonso Romero L, De Castro Ochoa M, Millán Jiménez A. Enfermedad celiaca: nuevos criterios diagnósticos. *Vox Paediatrica.* 2012; 19:28–33.
13. Green PHR. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. *Gastroenterology.* 2005;128(4):S74–S78.
14. Tosco A, Salvati VM, Auricchio R, et al. Natural history of potential celiac disease in children. *Clin Gastroenterol Hepatol.* 2011;9(4):320–325.
15. Green PH, Jabri B. Coeliac disease. *Lancet.* 2003;362:383–391.
16. Lionetti E, Catassi C. New clues in celiac disease epidemiology, pathogenesis, clinical manifestations, and treatment. *Int Rev Immunol.* 2011;30:219–231.
17. Bottaro G, Cataldo F, Rotolo N, et al. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. *Am J Gastroenterol.* 1999;94:691–696.
18. Rodrigo-Saez L, Fuentes-Alvarez D, Perez-Martinez I, et al. Differences between pediatric and adult celiac disease. *Rev Esp Enferm Dig.* 2011;103:238–244.
19. Murray JA, Watson T, Clearman B, et al. Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. *Am J Clin Nutr.* 2004;79:669–673.
20. Shamaly H, Mahameed A, Sharony A, Shamir R. Infertility and celiac disease: do we need more than one serological marker? *Acta Obstet Gynecol Scand.* 2004;83:1184–1188.
21. Malhotra P, Malhotra N, Malhotra V, et al. Infertility and celiac disease. *Indian J Parenter Enter Nutr.* 2016;4:26–27.
22. Singh P, Arora S, Lal S, et al. Celiac disease in women with infertility: a meta-analysis. *J Clin Gastroenterol.* 2016;50:33–39.

23. Lasa JS, Zubiaurre I, Soifer LO. Risk of infertility in patients with celiac disease: a meta-analysis of observational studies. *Arq Gastroenterol*. 2014;51: 144–150.

24. Meloni GF, Dessole S, Vargiu N, Tomasi PA, Musumeci S. The prevalence of coeliac disease in infertility. *Hum Reprod*. 1999;14:2759–2761.

25. Pietzak MM, Catassi C, Drago S, et al. Celiac disease: going against the grains. *Nutr Clin Pract*. 2001;16(6):335–344.

26. Withoff S, Li Y, Jonkers I, et al. Understanding celiac disease by genomics. *Trends Genet*. 2016;32:295–308.

27. Banaganapalli B, Rashidi O, Saadah OI, et al. Comprehensive Computational Analysis of GWAS Loci Identifies CCR2 as a Candidate Gene for Celiac Disease Pathogenesis. *J Cell Biochem*. January 2017.

28. van Heel DA, Hunt K, Greco L, et al. Genetics in coeliac disease. *Best Pract Res Clin Gastroenterol*. 2005;19:323–339.

29. Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. *Am J Gastroenterol*. 2008;103:190–195.

30. Monsuur AJ, Wijmenga C. Understanding the molecular basis of celiac disease: what genetic studies reveal. *Ann Med*. 2006;38:578–591.

31. Volta U, Villanacci V. Celiac disease: diagnostic criteria in progress. *Cell Mol Immunol*. 2011;8:96–102.

32. Clot F, Babron M-C. Genetics of celiac disease. *Mol Genet Metab*. 2000;71:76–80.

33. Kang J, Kang A, Green A, Gwee KA, Ho KY. Systematic review: worldwide variation in the frequency of coeliac disease and changes over time. *Aliment Pharmacol Ther*. 2013;38:226–245.

34. Kuja-Halkola R, Lebwohl B, Halfvarson J, Wijmenga C, Magnusson PKE, Ludvigsson JF. Heritability of non-HLA genetics in coeliac disease: a population-based study in 107 000 twins. *Gut*. 2016;65:1793–1798.

35. Fragoso Arbelo T, Díaz Lorenzo T, Pérez Ramos E, Pavón RM, Fragoso EL. Importancia de los aspectos psicosociales en la enfermedad celíaca. *Rev Cubana Med Gen Integr*. 2002;18:202–206.

36. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. *Arch Intern Med*. 2003;163:286–292.

37. Catassi C. The world map of celiac disease. *Acta Gastroenterol Latinoam*. 2005;35:37–55.

38. Dubé C, Rostom A, Sy R, et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. *Gastroenterology*. 2005;128:S57–S67.

39. Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. *Am J Gastroenterol*. 2012;107:1538–1544.

40. Gillett PM, Gillett HR, Israel DM, et al. High prevalence of celiac disease in patients with type 1 diabetes detected by antibodies to endomysium and tissue transglutaminase. *Can J Gastroenterol*. 2001;15:297–301.

41. Gomez JC, Selvaggio GS, Viola M, et al. Prevalence of celiac disease in Argentina: screening of an adult population in the La Plata area. *Am J Gastroenterol*. 2001;96:2700–2704.

42. Gandolfi L, Pratesi R, Cordoba JC, Tauil PL, Gasparin M, Catassi C. Prevalence of celiac disease among blood donors in Brazil. *Am J Gastroenterol*. 2000;95:689–692.

43. Araya M, Mondragon A, Perez-Bravo F, et al. Celiac disease in a Chilean population carrying Amerindian traits. *J Pediatr Gastroenterol Nutr*. 2000;31:381–386.

44. Rabassa EB, Sagaro E, Fragoso T, et al. Coeliac disease in Cuban children. *Arch Dis Child*. 1981;56:128–131.

45. Mustalahti K, Catassi C, Reunanen A, et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. *Ann Med*. 2010;42:587–595.

46. Catassi C, Fabiani E, Ratsch IM, et al. The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. *Acta Paediatr Suppl*. 1996;412:29–35.

47. Uibo O, Metskula K, Kukk T, Rägo T, Uibo R. Results of coeliac disease screening in Estonia in 1990–1994. *Acta Paediatr Suppl*. 1996;412:39–41.

48. Mäki M, Mustalahti K, Kokkonen J, et al. Prevalence of celiac disease among children in Finland. *N Engl J Med*. 2003;348:2517–2524.

49. Kratzer W, Kibele M, Akinli A, et al. Prevalence of celiac disease in Germany: a prospective follow-up study. *World J Gastroenterol*. 2013;19:2612–2620.

50. Korponay-Szabó IR, Kovács JB, Czinner A, Gorácz G, Vámos A, Szabó T. High prevalence of silent celiac disease in preschool children screened with IgA/IgG antiendomysium antibodies. *J Pediatr Gastroenterol Nutr*. 1999;28:26–30.

51. Schweizer JJ, von Blomberg BM, Bueno-de Mesquita HB, Mearin ML. Coeliac disease in the Netherlands. *Scand J Gastroenterol*. 2004;39:359–364.

52. Dobru D, Pascu O, Tanta M, et al. The prevalence of coeliac disease at endoscopy units in Romania: routine biopsies during gastroscopy are mandatory (a multicentre study). *Rom J Gastroenterol*. 2003;12:97–100.

53. Rutz R, Ritzler E, Fierz W, Herzog D. Prevalence of asymptomatic celiac disease in adolescents of eastern Switzerland. *Swiss Med Wkly*. 2002;132:43–47.

54. Cilleruelo Pascual ML, Roman Riechmann E, Jimenez Jimenez J, et al. Silent celiac disease: exploring the iceberg in the school-aged population. *An Esp Pediatr*. 2002;57:321–326.

55. Riestra S, Fernández E, Rodrigo L, Garcia S, Ocio G. Prevalence of coeliac disease in the general population of Northern Spain: strategies of serologic screening. *Scand J Gastroenterol*. 2000;35:398–402.

56. Antunes H, Abreu I, Nogueiras A, et al. First determination of the prevalence of celiac disease in a Portuguese population. *Acta Med Port*. 2006;19:115–120.

57. Mylotte M, Egan-Mitchell B, McCarthy CF, McNicholl B. Incidence of coeliac disease in the West of Ireland. *Br Med J*. 1973;1:703–705.

58. Sood A, Midha V, Sood N, Avasthi G, Sehgal A. Prevalence of celiac disease among school children in Punjab, North India. *J Gastroenterol Hepatol*. 2006;21:1622–1625.

59. Makharia GK, Verma AK, Amarchand R, et al. Prevalence of celiac disease in the northern part of India: a community based study. *J Gastroenterol Hepatol*. 2011;26:894–900.

60. Gursoy S, Guven K, Simsek T, et al. The prevalence of unrecognized adult celiac disease in Central Anatolia. *J Clin Gastroenterol*. 2005;39:508–511.

61. Akbari MR, Mohammadkhani A, Fakheri H, et al. Screening of the adult population in Iran for coeliac disease: comparison of the tissue-transglutaminase antibody and anti-endomysial antibody tests. *Eur J Gastroenterol Hepatol*. 2006;18:1181–1186.

62. Gujral N, Freeman HJ, Thomson ABR. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. *World J Gastroenterol*. 2012;18:6036–6059.

63. Shamir R, Lerner A, Shinar E, et al. The use of a single serological marker underestimates the prevalence of celiac disease in Israel: a study of blood donors. *Am J Gastroenterol*. 2002;97:2589–2594.

64. Jiang LL, Zhang BL, Liu YS. Is adult celiac disease really uncommon in Chinese? *J Zhejiang Univ Sci B*. 2009;10:168–171.

65. Cummins AG, Roberts-Thomson IC. Prevalence of celiac disease in the Asia-Pacific region. *J Gastroenterol Hepatol*. 2009;24:1347–1351.

66. Yap TWC, Chan WK, Leow AHR, et al. Prevalence of serum celiac antibodies in a multiracial Asian population—a first study in the young Asian adult population of Malaysia. *PLoS ONE*. 2015;10:e0121908.

67. Abu-Zekry M, Kryszak D, Diab M, Catassi C, Fasano A. Prevalence of celiac disease in Egyptian children disputes the east-west agriculture-dependent spread of the disease. *J Pediatr Gastroenterol Nutr*. 2008;47:136–140.

68. Catassi C, Ratsch I-M, Gandolfi L, et al. Why is coeliac disease endemic in the people of the Sahara? *Lancet*. 1999;354:647–648.

69. Hariz M Ben, Kallel-Sellami M, Kallel L, et al. Prevalence of celiac disease in Tunisia: mass-screening study in schoolchildren. *Eur J Gastroenterol Hepatol*. 2007;19(8):687–694.

70. Abu-Zeid YA, Jasem WS, Lebwohl B, Green PH, ElGhazali G. Seroprevalence of celiac disease among United Arab Emirates healthy adult nationals: a gender disparity. *World J Gastroenterol*. 2014;20:15830–15836.

71. Cook HB, Burt MJ, Collett JA, Whitehead MR, Frampton CM, Chapman BA. Adult coeliac disease: prevalence and clinical significance. *J Gastroenterol Hepatol*. 2000;15:1032–1036.

72. Chin MW, Mallon DF, Cullen DJ, Olynyk JK, Mollison LC, Pearce CB. Screening for coeliac disease using anti-tissue transglutaminase antibody assays, and prevalence of the disease in an Australian community. *Med J Aust*. 2009;190:429–432.

73. Freeman HJ. Biopsy-defined adult celiac disease in Asian-Canadians. *Can J Gastroenterol*. 2003;17:433–436.

74. Vivas S, Santolaria S. Enfermedad celiaca. Tratamineto de las Enfermedades Gastroenterológicas. 3a ed *Barcelona: Asoc Española Gastroenterol*. 2010: 265–278.

75. Rodrigo-Sáez L. Enfermedad celiaca. *Información Terapéutica del Sistema Nacional de Salud*. 2010;34(2):49–59.

76. Wahab PJ, Meijer JW, Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. *Am J Clin Pathol*. 2002;118:459–463.

77. Oberhuber G. Histopathology of celiac disease. *Biomed Pharmacother*. 2000;54:368–372.

78. Bai JC, Michael F, Corazza GR, et al. *Enfermedad celíaca*. Milwaukee, WI: World Gastroenterology Organization; 2012.

79. Grefte JM, Bouman JG, Grond J, Jansen W, Kleibeuker JH. Slow and incomplete histological and functional recovery in adult gluten sensitive enteropathy. *J Clin Pathol*. 1988;41:886–891.

80. Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease—effect of a gluten free diet. *Gut*. 1989;30:333–338.

81. Guandalini S, Assiri A. Celiac disease: a review. *JAMA Pediatr*. 2014;168:272–278.

82. Galatola M, Cielo D, Panico C, et al. Pre-symptomatic diagnosis of celiac disease in predisposed children: the role of gene expression profile [published online ahead of print January 20, 2017]. *J Pediatr Gastroenterol Nutr.* doi:10.1097/MPG.0000000000001519.

83. McAllister CS, Kagnoff MF. The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet. *Semin Immunopathol.* 2012;34:581–600.

84. Matoori S, Fuhrmann G, Leroux JC. Celiac disease: a challenging disease for pharmaceutical scientists. *Pharm Res.* 2013;30:619–626.

85. Rujner J, Socha J, Barra E, et al. Serum and salivary antigliadin antibodies and serum IgA anti-endomysium antibodies as a screening test for coeliac disease. *Acta Paediatr.* 1996;85:814–817.

86. Bonamico M, Nenna R, Montuori M, et al. First salivary screening of celiac disease by detection of anti-transglutaminase autoantibody radioimmunoassay in 5000 Italian primary schoolchildren. *J Pediatr Gastroenterol Nutr.* 2011;52:17–20.

87. Singh R, Nind G, Tucker G, et al. Narrow-band imaging in the evaluation of villous morphology: a feasibility study assessing a simplified classification and observer agreement. *Endoscopy.* 2010;42:889–894.

88. Picarelli A, Borghini R, Donato G, et al. Weaknesses of histological analysis in celiac disease diagnosis: new possible scenarios. *Scand J Gastroenterol.* 2014;49:1318–1324.

89. Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. *Nat Genet.* 2011;43:1193–1201.

90. Lie B, Sollid L, Ascher H, et al. A gene telomeric of the HLA class I region is involved in predisposition to both type 1 diabetes and coeliac disease. *Tissue Antigens.* 1999;54:162–168.

91. van Heel DA, Franke L, Hunt KA, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. *Nat Genet.* 2007;39:827–829.

92. Haimila K, Smedberg T, Mustalahti K, Mäki M, Partanen J, Holopainen P. Genetic association of coeliac disease susceptibility to polymorphisms in the ICOS gene on chromosome 2q33. *Genes Immun.* 2004;5:85–92.

93. Guo CC, Huang WH, Zhang N, et al. Association between IL2/IL21 and SH2B3 polymorphisms and risk of celiac disease: a meta-analysis. *Genet Mol Res.* 2015;14:13221–13235.

94. Hunt KA, Zhernakova A, Turner G, et al. Novel celiac disease genetic determinants related to the immune response. *Nat Genet.* 2008;40:395–402.

95. Barisani D, Ceroni S, Meneveri R, Cesana BM, Bardella MT. IL-10 polymorphisms are associated with early-onset celiac disease and severe mucosal damage in patients of Caucasian origin. *Genet Med.* 2006;8:169–174.

96. Lopez-Vazquez A, Rodrigo L, Fuentes D, et al. MHC class I chain related gene A (MICA) modulates the development of coeliac disease in patients with the high risk heterodimer DQA1*0501/DQB1*0201. *Gut.* 2002;50:336–340.

97. Kurppa K, Taavela J, Saavalainen P, Kaukinen K, Lindfors K. Novel diagnostic techniques for celiac disease. *Expert Rev Gastroenterol Hepatol.* 2016;10:795–805.

98. de Bakker PIW, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. *Nat Genet.* 2006;38:1166–1172.

99. Adamovic S, Amundsen SS, Lie BA, et al. Association study of IL2/IL21 and FcgRIIa: significant association with the IL2/IL21 region in Scandinavian coeliac disease families. *Genes Immun.* 2008;9:364–367.

100. Husby S, Koletzko S, Korponay-Szabo IR, et al. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. *J Pediatr Gastroenterol Nutr.* 2012;54:136–160.

101. Gonzalez S, Rodrigo L, Lopez-Vazquez A, et al. Association of MHC class I related gene B (MICB) to celiac disease. *Am J Gastroenterol.* 2004;99:676–680.

102. Adriaanse MP, Leffler DA, Kelly CP, et al. Serum I-FABP detects gluten responsiveness in adult celiac disease patients on a short-term gluten challenge. *Am J Gastroenterol.* 2016;111:1014–1022.

103. Moron B, Verma AK, Das P, et al. CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease. *Am J Gastroenterol.* 2013;108:1344–1351.

104. Pinier M, Verdu EF, Nasser-Eddine M, et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. *Gastroenterology.* 2009;136:288–298.

105. Goel G, King T, Daveson A, et al. 846 efficacy, safety, tolerability, and immunological effects of Nexvax2®, a peptide-based therapeutic vaccine, administered by intra-dermal (ID) injection twice-weekly for 8-weeks in HLA-DQ2.5+ celiac disease (CeD). *Gastroenterology.* 2016;150(4):S180.

106. Hollon JR, Cureton PA, Martin ML, Leonard Puppa EL, Fasano A. Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patients. *BMC Gastroenterol.* 2013;13(1):1–9.

107. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. *Gastroenterology.* 2001;120(3):636–651.

108. Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr.* 2005;40(1):1–19.

109. Collin P, Thorell L, Kaukinen K, Mäki M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? *Aliment Pharmacol Ther.* 2004;19:1277–1283.

110. Hlywiak KH. Hidden sources of gluten. *Pr Gastroenterol.* 2008;32:27–39.

111. Ludvigsson JF, Montgomery SM, Ekbom A, et al. Small-intestinal histopathology and mortality risk in celiac disease. *JAMA.* 2009;302(11):1171–1178.

112. Peters U, Askling J, Gridley G, Ekbom A, Linet M. Causes of death in patients with celiac disease in a population-based Swedish cohort. *Arch Intern Med.* 2003;163(3):1566–1572.

113. Malekzadeh R, Sachdev A, Ali AF. Coeliac disease in developing countries: Middle East, India and North Africa. *Best Pract Res Clin Gastroenterol.* 2005;19(3):351–358.